Utility and application of urine drug testing in chronic pain management with opioids

Clinical Journal of Pain

Volumn 25, Issue 1, 2009, Pages 73-79

  Nafziger, Anne N ^a   Bertino Jr , Joseph S ^a  

^a BERTINO CONSULTING   (United States)

Author keywords

Analgesics; Narcotics urine; Opioid therapeutic use; Pain drug therapy; Pharmacogenomics; Pharmacokinetics

Indexed keywords

CODEINE; CREATININE; FENTANYL; HYDROCODONE; HYDROMORPHONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ACCURACY; CHRONIC PAIN; CREATININE URINE LEVEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSPORT; DRUG URINE LEVEL; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; METHODOLOGY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; TREATMENT RESPONSE; URINALYSIS; CHRONIC DISEASE; PAIN; URINE;

ANALGESICS, OPIOID; CHRONIC DISEASE; CREATININE; HUMANS; PAIN;

EID: 62349107006     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31817e13cc     Document Type: Review

References (59)

1. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18: S76S82.
2. Manchikanti L, Manchukonda R, Damron KS, et al. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9:5760.
3. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9: 123129.
4. Center for Substance Abuse Work Force, Federation of State Medical Boards. Model policy guidelines for opioid addiction treatment in the medical o?ce. Pain Physician. 2003;6:217221.
5. Atluri S, Boswell MV, Hansen HC, et al. Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician. 2003;6:233257.
6. Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice, Dispelling the Myths and Designing Strategies. 3rd ed. Stamford, CT: PharmaCom Group; 2006:128.
7. Kahan M, Srivastava A, Wilson L, et al. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52:10811087.
8. Adams NJ, Plane MB, Fleming MF, et al. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage. 2001;22:791796.
9. Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:10971102.
10. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429444.
11. Osborne R, Joel S, Trew D, et al. Morphine and metabolite behavior after di?erent routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990;47: 1219.
12. BellMD, Murray GR, Mishra P, et al. Buccal morphinea new route for analgesia? Lancet. 1985;1:7173.
13. Nordberg G, Borg L, Hedner T, et al. CSF and plasma pharmacokinetics of intramuscular morphine. Eur J Clin Pharmacol. 1985;27:677681.
14. Oxycontin(R) Package Insert, 61 Edition. Montvale, Thompson Physicians Desk Reference, 2007.
15. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005;29:S57S66.
16. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltrans-ferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97132.
17. Gibaldi M, Perrier D. Pharmacokinetics. NY: Marcel Dekker Inc; 1975.
18. Kim RB. Transporters and drug discovery: why, when, and how. Mol Pharm. 2006;3:2632.
19. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem. 2005;280:96109617.
20. Hilli J, Rane A, Lundgren S, et al. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundam Clin Pharmacol. 2007;21:379386.
21. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005;33:16031607.
22. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics a?ects dosing, e?cacy, and toxicity of cytochrome P450- metabolized drugs. Am J Med. 2002;113:746750.
23. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7:257265.
24. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther. 2008;83: 225227.
25. Spear BB, Heath-Chiozzi M, Hu? J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201204.
26. Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004;57:287297.
27. Duragesic(R) Package Insert, 61 Edition. Montvale, Thompson Physicians Desk Reference, 2007.
28. AHFS Drug Information. Bethesda, American Society of Health-System Pharmacists, 2004.
29. Totah RA, Allen KE, She?els P, et al. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321:389399.
30. Kharasch ED, Ho?er C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic e?ects of methadone. Clin Pharmacol Ther. 2004;76:250269.
31. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447454.
32. Paar WD, Poche S, Gerlo? J, et al. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53:235239.
33. Subrahmanyam V, Renwick AB, Walters DG, et al. Identi?cation of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001;29:11461155.
34. Bernard JP, OpdalMS, Karinen R, et al. Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphe- nylpyrrolidine) in urine samples from Norwegian prisons. Eur J Clin Pharmacol. 2007;63:777782.
35. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002;34:83448.
36. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:11531193.
37. Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer. 2005;13:145152.
38. Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:9831013.
39. Popa C, Beck O, Brodin K. Morphine formation from ethylmorphine: implications for drugs-of-abuse testing in urine. J Anal Toxicol. 1998;22:142147.
40. Streetman DS, Ellis RE, Nafziger AN, et al. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther. 1999;66:535541.
41. Lee LS, Nafziger AN, Bertino JS Jr. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther. 2005;78:16.
42. Chen M, Ma L, Drusano GL, et al. Sex di?erences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006;80:531538.
43. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38: 978988.
44. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, e?cacy, and drug interactions. Drug Metab Dispos. 1997;25:10721080.
45. Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide-to-morphine plasma ratios are una?ected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol. 2002;58:353356.
46. Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical signi?cance. Pharmacogenetics. 2000;10: 679685.
47. Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003;73: 566574.
48. Leavitt SB, Shinderman M, Maxwell S, et al. When enough is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 2000;67:404411.
49. Campa D, Gioia A, Tomei A, et al. Association of ABCB1/ MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. Clin Pharmacol Ther. 2008;83:559566.
50. Deferme S, Augustijns P. The e?ect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol. 2003;55:153162.
51. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: e?ective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol. 2000;55: 713719.
52. Paradigm Management Services, LLC and Ameritox An-nounce a Partnership in Using RxGuardian to Manage Chronic Pain Cases, 2008, pp press release. 53. Janicki P. Interindividual Di?erences in Opioid Analgesic Usage in Chronic Pain Patients in Relationship to A118G Mu- Opioid Receptor Polymorphism. Pain Med. 2005;6:176177.
53. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006;79:316324.
54. Manno J. Interpretation of Urinalysis Results, NIDA Research Monograph: Urine Testing for Drugs of Abuse. In: Hawks RL, Chiang CN, eds. Rockville: Department of Health and Human Services; 1986:5460.
55. Cook JD, Caplan YH, LoDico CP, et al. The characterization of human urine for specimen validity determination in work- place drug testing: a review. J Anal Toxicol. 2000;24:579588.
56. Springhouse Corporation. Handbook of Diagnostic Tests. 2nd ed. Springhouse: Springhouse Corporation; 1999.
57. Ceder G, Jones AW. Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem. 2001;47: 19801984.
58. Webster LR,Medve R, Backer RC. Evaluation of a proprietary algorithm to provide a clinical adjunct to predicting dose compliance, International Conference on Pain and Chemical Dependency. New York City; 2007.
59. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260267.